Newborn screening testing services
Active Purchase Order Awarded Last action
- Contract number
- W81K0024P0217
- Awardee
-
Revvity Omics Inc. UEI LDJULX8K6M85 Part of Revvity Inc.
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $324,512
Award facts
- Opportunity
-
- Newborn Genetic Testing - William Beaumont Army Medical Center (Fort Bliss, Texas) Solicitation · W81K0024Q0143 · Posted Jul 26, 2024
- Contract value 38% obligated
-
- $494,096.00 Current, with exercised options
- $848,688.00 Potential, with all options
- Completion date 41% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- Funding agency
- Defense Health Agency Department of Defense
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Pittsburgh, PA 15275, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $0 | |
| Funding Only Action | $164,656 | |
| Exercise an Option | $0 | |
| Funding Only Action | $159,856 | |
| Original award | $0 |
About this award
The Defense Health Agency awarded a firm fixed-price purchase order valued at $848,688 to Revvity Omics Inc. (doing business as PerkinElmer Genetics) on October 1, 2024, for newborn genetic testing services at William Beaumont Army Medical Center in Fort Bliss, Texas. The contract extends through September 30, 2029, with no small business set-aside designation. The award fulfills a Department of the Army Medical Command solicitation issued in July 2024 seeking a contractor to conduct a comprehensive 13-condition newborn genetic screening panel, including tests for glucose-6-phosphate dehydrogenase deficiency, cystic fibrosis, and congenital hypothyroidism. The contractor must maintain CAP/CLIA accreditation and FDA licensing, deliver initial results within 72 hours, and complete confirmatory testing within 5-10 business days.
Revvity Omics Inc., a subsidiary of Revvity Inc., is an established provider of newborn screening and genetic testing services exclusively to military healthcare facilities. The company has an active federal contracting portfolio that includes multiple indefinite delivery contracts and blanket purchase agreements with the Defense Health Agency and Department of the Air Force for comparable newborn metabolic screening services at military treatment facilities in South Korea, Germany, and the continental United States, demonstrating sustained capability and performance in this specialized market. This William Beaumont contract represents approximately 1,600 annual tests per condition and consolidates Revvity's role as a primary newborn screening provider within the military health system.
Quick answers
Who was awarded contract W81K0024P0217?
W81K0024P0217 was awarded to Revvity Omics Inc. by Medical Command (Department of the Army) on October 1, 2024.
How much is contract W81K0024P0217 worth?
The government has obligated $324,512 on W81K0024P0217. Its current value, with exercised options, is $494,096. Its potential value, with all options, is $848,688.
Which agency awarded contract W81K0024P0217?
Medical Command (Department of the Army) awarded W81K0024P0217, with funding from Defense Health Agency (Department of Defense).
Was contract W81K0024P0217 competed?
The extent of competition for W81K0024P0217 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award